BIGBEAR
PHARMACEUTICAL
Selpercatinib is a highly selective and potent kinase inhibitor that exerts its therapeutic effect by selectively targeting and inhibiting mutated or fusion forms of the RET gene.
AuthenticGuaranteeFast DeliveryPrivacy The U.S. FDA recently approved Retevmo (selpercatinib, 40 mg and 80 mg capsules), a targeted anticancer drug from Eli Lilly subsidiary LoxoOncology, f···【More】
Update: 19 Mar,2026Source: BigbearViews: 113
On May 8, 2020, the U.S. Food and Drug Administration (FDA) accelerated the approval of the oral kinase inhibitor Retevmo (selpercatinib; LillyOncolog···【More】
Update: 19 Mar,2026Source: BigbearViews: 111
On September 21, 2022, Eli Lilly and Company announced that the FDA has granted accelerated approval to Retevmo (selpercatinib) for the treatment of a···【More】
Update: 19 Mar,2026Source: BigbearViews: 117
According to a May 29th press release from the U.S. FDA, Retevmo (selpercatinib) from Eli Lilly is approved for the treatment of children aged 2 years···【More】
Update: 19 Mar,2026Source: BigbearViews: 109
The U.S. FDA recently granted conventional approval to Eli Lilly's selective RET kinase inhibitor Retevmo (selpercatinib) for the treatment of adu···【More】
Update: 19 Mar,2026Source: BigbearViews: 110
According to Eli Lilly, the U.S. Food and Drug Administration (FDA) announced on September 27 that it has granted regular approval to the RET inhibito···【More】
Update: 19 Mar,2026Source: BigbearViews: 110
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
